Abstract:Background. Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, affects approximately one-quarter of the global population and is considered one of the most lethal infectious diseases worldwide. The prevention of latent tuberculosis infection (LTBI) from progressing into active tuberculosis (ATB) is crucial for controlling and eradicating TB. Unfortunately, currently available biomarkers have limited effectiveness in identifying subpopulations that are at risk of developing ATB. Hence, it is imperative to develop advanced molecular tools for TB risk stratification. Methods. The TB datasets were downloaded from the GEO database. Three machine learning models, namely LASSO, RF, and SVM-RFE, were used to identify the key characteristic genes related to inflammation during the progression of LTBI to ATB. The expression and diagnostic accuracy of these characteristic genes were subsequently verified. These genes were then used to develop diagnostic nomograms. In addition, single-cell expression clustering analysis, immune cell expression clustering analysis, GSVA analysis, immune cell correlation, and immune checkpoint correlation of characteristic genes were conducted. Furthermore, the upstream shared miRNA was predicted, and a miRNA–genes network was constructed. Candidate drugs were also analyzed and predicted. Results. In comparison to LTBI, a total of 96 upregulated and 26 downregulated genes related to the inflammatory response were identified in ATB. These characteristic genes have demonstrated excellent diagnostic performance and significant correlation with many immune cells and immune sites. The results of the miRNA–genes network analysis suggested a potential role of hsa-miR-3163 in the molecular mechanism of LTBI progressing into ATB. Moreover, retinoic acid may offer a potential avenue for the prevention of LTBI progression to ATB and for the treatment of ATB. Conclusion. Our research has identified key inflammatory response-related genes that are characteristic of LTBI progression to ATB and hsa-miR-3163 as a significant node in the molecular mechanism of this progression. Our analyses have demonstrated the excellent diagnostic performance of these characteristic genes and their significant correlation with many immune cells and immune checkpoints. The CD274 immune checkpoint presents a promising target for the prevention and treatment of ATB. Furthermore, our findings suggest that retinoic acid may have a role in preventing LTBI from progressing to ATB and in treating ATB. This study provides a new perspective for differential diagnosis of LTBI and ATB and may uncover potential inflammatory immune mechanisms, biomarkers, therapeutic targets, and effective drugs in the progression of LTBI into ATB.

Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study

Plasma Metabolomic and Lipidomic Alterations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Longitudinal metabolomics of human plasma reveal metabolic dynamics and predictive markers of antituberculosis drug-induced liver injury

Metabolomics and microbiomes for discovering biomarkers of antituberculosis drugs-induced hepatotoxicity

Predicting Antituberculosis Drug-Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study

Discovery of urinary biosignatures for tuberculosis and nontuberculous mycobacteria classification using metabolomics and machine learning

Urinary metabolomic analysis to identify potential markers for the diagnosis of tuberculosis and latent tuberculosis

Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury.

Interpretable Machine Learning in Predicting Drug-Induced Liver Injury among Tuberculosis Patients: Model Development and Validation Study

First-line Anti-Tuberculosis Drugs Induce Hepatotoxicity: A Novel Mechanism Based on a Urinary Metabolomics Platform.

The Feasibility of using Liver Function Indices and FibroScan in combination to predict the occurrence of anti-tuberculosis drug-induced liver injury in patients with liver disease

Risk Factors of Anti-Tuberculosis Drugs Induced Liver Injury and Its Impact on the Treatment Outcome of Patients Treated with First Line Anti-Tuberculosis Drugs: a Historic Retrospective Cohort Study

Interpretable Deep Learning for Drug-Induced Liver Injury among Patients with Tuberculosis: Model Development and Validation Study (Preprint)

Untargeted Metabolomics of Feces Reveals Diagnostic and Prognostic Biomarkers for Active Tuberculosis and Latent Tuberculosis Infection: Potential Application for Precise and Non-Invasive Identification.

Combined Electronic Medical Records and Gene Polymorphism Characteristics to Establish an Anti-Tuberculosis Drug-Induced Hepatic Injury (ATDH) Prediction Model and Evaluate the Prediction Value

An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis

Predicting the Progress of Tuberculosis by Inflammatory Response-Related Genes Based on Multiple Machine Learning Comprehensive Analysis

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

The role of genetic polymorphism in predictive model of ATDH

Identification of Potential Urine Proteins and Microrna Biomarkers for the Diagnosis of Pulmonary Tuberculosis Patients.

Alterations in purine and pyrimidine metabolism associated with latent tuberculosis infection: insights from gut microbiome and metabolomics analyses